company background image
TBIO

Translate BioNasdaqGS:TBIO Stock Report

Market Cap

US$2.8b

7D

-0.5%

1Y

161.4%

Updated

15 Sep, 2021

Data

Company Financials +
TBIO fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance3/6
Financial Health6/6
Dividends0/6

TBIO Overview

Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction.

Translate Bio Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Translate Bio
Historical stock prices
Current Share PriceUS$37.36
52 Week HighUS$11.91
52 Week LowUS$37.99
Beta0.97
1 Month Change-0.80%
3 Month Change99.15%
1 Year Change161.44%
3 Year Change261.32%
5 Year Changen/a
Change since IPO224.31%

Recent News & Updates

Shareholder Returns

TBIOUS BiotechsUS Market
7D-0.5%-2.3%0.1%
1Y161.4%26.1%35.3%

Return vs Industry: TBIO exceeded the US Biotechs industry which returned 23.4% over the past year.

Return vs Market: TBIO exceeded the US Market which returned 30.7% over the past year.

Price Volatility

Is TBIO's price volatile compared to industry and market?
TBIO volatility
TBIO Beta0.97
Industry Beta1.03
Market Beta1

Stable Share Price: TBIO is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: TBIO's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2011122Ron Renaudhttps://www.translate.bio

Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis. It is also developing MRT5500 for the treatment of SARS-CoV-2.

Translate Bio Fundamentals Summary

How do Translate Bio's earnings and revenue compare to its market cap?
TBIO fundamental statistics
Market CapUS$2.82b
Earnings (TTM)US$40.45m
Revenue (TTM)US$225.09m

69.8x

P/E Ratio

12.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
TBIO income statement (TTM)
RevenueUS$225.09m
Cost of RevenueUS$73.98m
Gross ProfitUS$151.11m
ExpensesUS$110.66m
EarningsUS$40.45m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.54
Gross Margin67.13%
Net Profit Margin17.97%
Debt/Equity Ratio0%

How did TBIO perform over the long term?

See historical performance and comparison

Valuation

Is Translate Bio undervalued compared to its fair value and its price relative to the market?

69.82x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate TBIO's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate TBIO's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: TBIO is poor value based on its PE Ratio (69.8x) compared to the US Biotechs industry average (24.4x).

PE vs Market: TBIO is poor value based on its PE Ratio (69.8x) compared to the US market (17.1x).


Price to Earnings Growth Ratio

PEG Ratio: TBIO's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: Insufficient data to calculate TBIO's PB Ratio to determine if it is good value.


Future Growth

How is Translate Bio forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

-45.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TBIO's earnings are forecast to decline over the next 3 years (-45.2% per year).

Earnings vs Market: TBIO's earnings are forecast to decline over the next 3 years (-45.2% per year).

High Growth Earnings: TBIO's earnings are forecast to decline over the next 3 years.

Revenue vs Market: TBIO's revenue is expected to decline over the next 3 years (-5% per year).

High Growth Revenue: TBIO's revenue is forecast to decline over the next 3 years (-5% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: TBIO's Return on Equity is forecast to be low in 3 years time (1%).


Past Performance

How has Translate Bio performed over the past 5 years?

10.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: TBIO has high quality earnings.

Growing Profit Margin: TBIO became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: TBIO has become profitable over the past 5 years, growing earnings by 10.3% per year.

Accelerating Growth: TBIO has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: TBIO has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).


Return on Equity

High ROE: TBIO's Return on Equity (9.8%) is considered low.


Financial Health

How is Translate Bio's financial position?


Financial Position Analysis

Short Term Liabilities: TBIO's short term assets ($717.0M) exceed its short term liabilities ($81.5M).

Long Term Liabilities: TBIO's short term assets ($717.0M) exceed its long term liabilities ($410.7M).


Debt to Equity History and Analysis

Debt Level: TBIO is debt free.

Reducing Debt: TBIO has not had any debt for past 5 years.

Debt Coverage: TBIO has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: TBIO has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Translate Bio current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate TBIO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate TBIO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TBIO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TBIO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TBIO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Ron Renaud (52 yo)

6.83yrs

Tenure

US$3,337,223

Compensation

Mr. Ronald C. Renaud, Jr., also known as Ron, MBA, has been the Chief Executive Officer of Translate Bio, Inc. since November 2014 and served as its Interim Principal Financial Officer since December 27, 2...


CEO Compensation Analysis

Compensation vs Market: Ron's total compensation ($USD3.34M) is below average for companies of similar size in the US market ($USD5.19M).

Compensation vs Earnings: Ron's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: TBIO's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

Experienced Board: TBIO's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: TBIO insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Translate Bio, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Translate Bio, Inc.
  • Ticker: TBIO
  • Exchange: NasdaqGS
  • Founded: 2011
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$2.824b
  • Shares outstanding: 75.59m
  • Website: https://www.translate.bio

Number of Employees


Location

  • Translate Bio, Inc.
  • 29 Hartwell Avenue
  • Lexington
  • Massachusetts
  • 2421
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/15 08:32
End of Day Share Price2021/09/13 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.